Beijing Tong Ren Tang Chinese Medicine (HKG:3613) recorded a 6.9% rise in attributable profit in the first half of 2025 to HK$234.9 million from HK$219.8 million in the year-ago period, a Friday Hong Kong bourse filing said.

Earnings per share were HK$0.28 in the half year, up from HK$0.26 in the corresponding period of the last year.

Revenue for the medicine manufacturer rose 15% to HK$761.7 million in the interim period from HK$664.5 million a year prior.